<DOC>
	<DOC>NCT01631214</DOC>
	<brief_summary>The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis</brief_summary>
	<brief_title>Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Postmenopausal women with osteoporosis at high risk for fracture defined as: 1. a hip BMD Tscore of ≤2.5 SD and a vertebral fracture or 2. a hip BMD Tscore of ≤2.0 SD and a recent hip fracture or two vertebral fractures. History of metabolic or bone disease (except osteoporosis) Use of agents affecting bone metabolism Vitamin D insufficiency History of solid organ or bone marrow transplants Hyper or hypocalcemia Hyper or hypothyroidism Hyper or hypoparathyroidism Possible signs of intolerance to Alendronate</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoporosis, Osteoporosis-postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases</keyword>
</DOC>